• 1
    Scott DL, Wolfe F, Huizinga TW.Rheumatoid arthritis.Lancet2010;376:1094108.
  • 2
    McInnes IB, Schett G.The pathogenesis of rheumatoid arthritis.N Engl J Med2011;365:220519.
  • 3
    Kremer JM.Toward a better understanding of methotrexate.Arthritis Rheum2004;50:137082.
  • 4
    Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P.New therapies for treatment of rheumatoid arthritis.Lancet2007;370:186174.
  • 5
    Gonen N, Assaraf YG.Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance.Drug Resist Updat2012;15:183210.
  • 6
    Bertino JR.Karnofsky memorial lecture: ode to methotrexate.J Clin Oncol1993;11:514.
  • 7
    Cronstein BN.Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis.Pharmacol Rev2005;57:16372.
  • 8
    Cutolo M, Sulli A, Pizzorni C, Seriolo B, Straub RH.Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis.Ann Rheum Dis2001;60:72935.
  • 9
    Spurlock CF III, Tossberg JT, Fuchs HA, Olsen NJ, Aune TM.Methotrexate increases expression of cell cycle checkpoint genes via JNK activation.Arthritis Rheum2012;64:17809.
  • 10
    Phillips DC, Woollard KJ, Griffiths HR.The anti-inflammatory actions of methotrexate are critically dependent upon the production of reactive oxygen species.Br J Pharmacol2003;138:50111.
  • 11
    Genestier L, Paillot R, Fournel S, Ferraro C, Miossec P, Revillard JP.Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells.J Clin Invest1998;102:3228.
  • 12
    Majumdar S, Aggarwal BB.Methotrexate suppresses NF-κB activation through inhibition of IκBα phosphorylation and degradation.J Immunol2001;167:291120.
  • 13
    Van der Heijden JW, Dijkmans BA, Scheper RJ, Jansen G.Drug insight: resistance to methotrexate and other disease-modifying antirheumatic drugs—from bench to bedside.Nat Clin Pract Rheumatol2007;3:2634.
  • 14
    Qiu A, Jansen M, Sakaris A, Min SH, Chattopadhyay S, Tsai E, et al.Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption.Cell2006;127:91728.
  • 15
    Nakashima-Matsushita N, Homma T, Yu S, Matsuda T, Sunahara N, Nakamura T, et al.Selective expression of folate receptor β and its possible role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis.Arthritis Rheum1999;42:160916.
  • 16
    Van der Heijden JW, Oerlemans R, Dijkmans BA, Qi H, van der Laken CJ, Lems WF, et al.Folate receptor β as a potential delivery route for novel folate antagonists to macrophages in the synovial tissue of rheumatoid arthritis patients.Arthritis Rheum2009;60:1221.
  • 17
    Stark M, Wichman C, Avivi I, Assaraf YG.Aberrant splicing of folylpolyglutamate synthetase as a novel mechanism of antifolate resistance in leukemia.Blood2009;113:43629.
  • 18
    Rots MG, Pieters R, Peters GJ, Noordhuis P, van Zantwijk CH, Kaspers GJ, et al.Role of folylpolyglutamate synthetase and folylpolyglutamate hydrolase in methotrexate accumulation and polyglutamylation in childhood leukemia.Blood1999;93:167783.
  • 19
    Baggott JE, Morgan SL, Vaughn WH.Differences in methotrexate and 7-hydroxymethotrexate inhibition of folate-dependent enzymes of purine nucleotide biosynthesis.Biochem J1994;300:6279.
  • 20
    Allegra CJ, Drake JC, Jolivet J, Chabner BA.Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates.Proc Natl Acad Sci U S A1985;82:48815.
  • 21
    Hooijberg JH, Broxterman HJ, Kool M, Assaraf YG, Peters GJ, Noordhuis P, et al.Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2.Cancer Res1999;59:25325.
  • 22
    Wessels JA, van der Kooij SM, le Cessie S, Kievit W, Barerra P, Allaart CF, et al.A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis.Arthritis Rheum2007;56:176575.
  • 23
    Stamp LK, Roberts RL.Effect of genetic polymorphisms in the folate pathway on methotrexate therapy in rheumatic diseases.Pharmacogenomics2011;12:144963.
  • 24
    Fransen J, Kooloos WM, Wessels JA, Huizinga TW, Guchelaar HJ, van Riel PL, et al.Clinical pharmacogenetic model to predict response of MTX monotherapy in patients with established rheumatoid arthritis after DMARD failure.Pharmacogenomics2012;13:108794.
  • 25
    Dervieux T, Zablocki R, Kremer J.Red blood cell methotrexate polyglutamates emerge as a function of dosage intensity and route of administration during pulse methotrexate therapy in rheumatoid arthritis.Rheumatology (Oxford)2010;49:233745.
  • 26
    Stamp LK, O'Donnell JL, Chapman PT, Zhang M, James J, Frampton C, et al.Methotrexate polyglutamate concentrations are not associated with disease control in rheumatoid arthritis patients receiving long-term methotrexate therapy.Arthritis Rheum2010;62:35968.
  • 27
    Van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, Voskuyl AE, Rustenburg F, Baggen JM, et al.Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients.Ann Rheum Dis2007;66:100814.
  • 28
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al.The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.Arthritis Rheum1988;31:31524.
  • 29
    Chaussabel D, Pascual V, Banchereau J.Assessing the human immune system through blood transcriptomics.BMC Biol2010;8:84.
  • 30
    Ball CA, Awad IA, Demeter J, Gollub J, Hebert JM, Hernandez-Boussard T, et al.The Stanford Microarray Database accommodates additional microarray platforms and data formats.Nucleic Acids Res2005;33:D5802.
  • 31
    Tusher VG, Tibshirani R, Chu G.Significance analysis of microarrays applied to the ionizing radiation response.Proc Natl Acad Sci U S A2001;98:511621.
  • 32
    Batliwalla FM, Baechler EC, Xiao X, Li W, Balasubramanian S, Khalili H, et al.Peripheral blood gene expression profiling in rheumatoid arthritis.Genes Immun2005;6:38897.
  • 33
    Van Baarsen LG, Wijbrandts CA, Gerlag DM, Rustenburg F, van der Pouw Kraan TC, Dijkmans BA, et al.Pharmacogenomics of infliximab treatment using peripheral blood cells of patients with rheumatoid arthritis.Genes Immun2010;11:6229.
  • 34
    Mattson MP, Shea TB.Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders.Trends Neurosci2003;26:13746.
  • 35
    Viswanathan GA, Seto J, Patil S, Nudelman G, Sealfon SC.Getting started in biological pathway construction and analysis.PLoS Comput Biol2008;4:e16.
  • 36
    Tibbetts AS, Appling DR.Compartmentalization of mammalian folate-mediated one-carbon metabolism.Annu Rev Nutr2010;30:5781.
  • 37
    Van der Heijden JW, Oerlemans R, Tak PP, Assaraf YG, Kraan MC, Scheffer GL, et al.Involvement of breast cancer resistance protein expression on rheumatoid arthritis synovial tissue macrophages in resistance to methotrexate and leflunomide.Arthritis Rheum2009;60:66977.
  • 38
    Van de Ven R, Oerlemans R, van der Heijden JW, Scheffer GL, de Gruijl TD, Jansen G, et al.ABC drug transporters and immunity: novel therapeutic targets in autoimmunity and cancer.J Leukoc Biol2009;86:107587.
  • 39
    De Rotte MC, Luime JJ, Bulatovic M, Hazes JM, Wulffraat NM, de Jonge R.Do snapshot statistics fool us in MTX pharmacogenetic studies in arthritis research?Rheumatology (Oxford)2010;49:12001.
  • 40
    Owen SA, Hider SL, Martin P, Bruce IN, Barton A, Thomson W.Genetic polymorphisms in key methotrexate pathway genes are associated with response to treatment in rheumatoid arthritis patients.Pharmacogenomics J2013;13:22734.
  • 41
    Dalrymple JM, Stamp LK, O'Donnell JL, Chapman PT, Zhang M, Barclay ML.Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis.Arthritis Rheum2008;58:3299308.
  • 42
    Dervieux T, Furst D, Lein DO, Capps R, Smith K, Walsh M, et al.Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis.Arthritis Rheum2004;50:276674.
  • 43
    Dervieux T, Wessels JA, Kremer JM, Padyukov L, Seddighzadeh M, Saevarsdottir S, et al.Patterns of interaction between genetic and nongenetic attributes and methotrexate efficacy in rheumatoid arthritis.Pharmacogenet Genomics2012;22:19.
  • 44
    Burmester GR, Mariette X, Montecucco C, Monteagudo-Saez I, Malaise M, Tzioufas AG, et al.Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial.Ann Rheum Dis2007;66:7329.
  • 45
    Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al.Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial.Lancet2004;363:67581.
  • 46
    Emery P, Genovese MC, van Vollenhoven R, Sharp JT, Patra K, Sasso EH.Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis.J Rheumatol2009;36:142941.
  • 47
    Walling J.From methotrexate to pemetrexed and beyond: a review of the pharmacodynamic and clinical properties of antifolates.Invest New Drugs2006;24:3777.
  • 48
    Westerhof GR, Schornagel JH, Kathmann I, Jackman AL, Rosokowsky A, Forsch RA, et al.Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity.Mol Pharmacol1995;48:45971.
  • 49
    Nagayoshi R, Nakamura M, Ijiri K, Yoshida H, Komiya S, Matsuyama T.LY309887, antifolate via the folate receptor suppresses murine type II collagen-induced arthritis.Clin Exp Rheumatol2003;21:71925.
  • 50
    Jansen G, Mauritz R, Kathmann I, Boritzki TJ, Peters GJ.Membrane transport properties and biological activity of stereo-isomers of glycinamide ribonucleotide formyltransferase (GARTF) inhibitors AG2032 and AG2034.Pteridines2010;20:10914.